Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

2012737 citationsJournal Articlebronze Open Access

Authors

Antonio Palumbo · University of Turin

Roman Hájek · University Hospital Brno

Michel Delforge

Martin Kropff · University of Münster

Maria Teresa Petrucci · Sapienza University of Rome

John Catalano · Monash University

Heinz Gisslinger · Medical University of Vienna

Abstract

MPR-R significantly prolonged progression-free survival in patients with newly diagnosed multiple myeloma who were ineligible for transplantation, with the greatest benefit observed in patients 65 to 75 years of age. (Funded by Celgene; MM-015 ClinicalTrials.gov number, NCT00405756.).

Topics & Keywords

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Research on Leishmaniasis Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 19, pp. 1759-1769

DOI: 10.1056/nejmoa1112704

Field-Weighted Citation Impact: 54.10